论文部分内容阅读
考察他莫昔芬联合依维莫司对雌激素受体 (Estrogen receptor, ER) 阳性转移性乳腺癌的临床治疗效果.将116例ER阳性转移性乳腺癌患者随机分为观察组和对照组, 每组58例.对照组患者给予他莫昔芬单药治疗, 观察组患者在此基础上加用依维莫司治疗.比较两组患者整体治疗效果、血清标记物水平变化及不良反应.观察组患者临床获益率显著高于对照组患者 (P0.05), 治疗后观察组患者血清CEA、CA153、CA125水平显著低于对照组患者 (P<0.01).观察组患者咳嗽发生率显著高于对照组患者 (x2=4.419, P<0.05).由此可知, 他莫昔芬联合依维莫司对ER阳性转移性乳腺癌患者临床治疗效果更优, 安全可靠具有临床应用价值.“,”To investigate the clinical effect of Tamoxifen combined with Everolimus on ER positive metastatic breast cancer, 116 patients with ER positive metastatic breast cancer were randomly divided into the observation group and the control group, with 58 cases in each group.The control group were given Tamoxifen monotherapy and the patients in the observation group were based on the use of Everolimus treatment.The overall treatment effect, the level of serum markers and adverse reactions were compared between the two groups.The clinical benefit rate of the patients in the observation group was significantly higher than that of the control group (P 0.05).After treatment, the levels of serum CEA, CA153 and CA125 in the observation group were significantly lower than those in the control group (P < 0.01).The incidence of cough in the observation group was significantly higher than that in the control group (x2= 4.419, P < 0.05).In summary, the clinical effect of Tamoxifen combined with Everolimus in the patients with ER positive metastatic breast cancer was safe and reliable with clinical value.